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Abstract
Background: There have been few studies of pulmonary actinomycosis, which is an uncommon anaerobic
infection. Consequently, the optimal therapeutic regimen, appropriate duration of treatment, long-term prognosis,
and factors predicting prognosis are not well established.
Methods: We retrospectively reviewed the medical records of histopathologically confirmed cases of pulmonary
actinomycosis seen between November 2003 and December 2012.
Results: The study included 68 patients with a mean age of 58.4 ± 11.6 years. Of the 68, initial surgery was
performed in 15 patients (22.1%), while the remaining 53 (77.9%) received antibiotic therapy initially. In the initial
antibiotic group, 45/53 (84.9%) were cured without relapse (median antibiotic duration 5.3 months). 5/53 (9.4%)
patients were refractory medically (median antibiotic duration 9.7 months), and 3/53 (5.7%) experienced a
recurrence (median time to relapse 35.3 months). In the initial surgery group, 14/15 (93.3%) were cured and
treatment failure occurred in one (6.7%). In the multivariate analysis, the absence of an antibiotic response at
1 month was the only independent factor associated with a poor treatment outcome, with an adjusted odds ratio
of 49.2 (95% CI, 3.34–724.30). There was no significant difference in treatment outcome based on the size of the
parenchymal lesion, comorbidities, whether intravenous antibiotics were used, antibiotic therapy duration, or
whether the initial treatment was surgical.
Conclusions: Antibiotic treatment with or without surgery was effective for treatment of pulmonary actinomycosis.
Nevertheless, treatment failure or recurrence occurred in a considerable proportion of patients, especially those
resistant to the initial antibiotic treatment.
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Background
Actinomycosis is a chronic, slowly progressive granu-
lomatous disease caused by filamentous Gram-positive
anaerobic or microaerophilic bacteria of the family Acti-
nomycetaceae (genus Actinomyces) [1]. These normally
colonize the mouth, colon, and vagina [2]. This can lead
to infection at virtually any site in the body; pulmonary
actinomycosis accounts for 15% of all actinomycosis
cases [1,3]. Infection is thought to result from the inhal-
ation or aspiration of oropharyngeal or upper gastro-
intestinal materials [1,4].
Pulmonary actinomycosis is difficult to diagnose and
needs prolonged antibiotic treatment [1]. The diagnosis
is suspected on admission in only 7–18% of patients who
later turn out to have an actinomycosis infection [5,6].
Traditionally, patients with pulmonary actinomycosis are
treated with high-dose intravenous (IV) penicillin at a
dose of 18–24 million units daily for 2–6 weeks, followed
by oral penicillin or amoxicillin for 6–12 months [2]. The
principles of intensive, prolonged therapy were recom-
mended in the late 1950s based on clinical experience
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[7,8]. However, the evidence for this recommendation is
weak. Furthermore, several investigators have successfully
treated extensive pulmonary actinomycosis with relatively
brief courses of antibiotics [9,10]. Conversely, a recent
study showed that medical treatment failure can occur in
patients receiving appropriate antibiotics for pulmonary
actinomycosis [6]. This is incompatible with the traditional
concept of a medically treatable disease with a good prog-
nosis [5]. However, no randomized controlled trial or
large-scale retrospective study has compared antibiotic
regimens or treatment modalities.
In this retrospective study, we investigated the long-
term prognosis of pulmonary actinomycosis, evaluated
the efficacy of specific antibiotics, and identified the clin-
ical parameters predicting the treatment outcome.
Methods
Study population
We reviewed retrospectively the medical records of all
patients with pulmonary actinomycosis seen at Seoul
National University Bundang Hospital and Seoul National
University Hospital between November 2003 and December
2012. This study was approved by the institutional re-
view board of Seoul National University Bundang Hospital
(B-1210-176-114).
Study design and data acquisition
We selected patients whose actinomycosis lesions were
confirmed by biopsy, using either surgical or nonsurgi-
cal methods. We collected clinical data on the patients,
including smoking status, alcohol consumption, edu-
cation status, underlying systemic disease, pulmonary
comorbidity, diagnostic methods, and treatment mo-
dalities. We also reviewed the initial chest computed
tomography (CT) images, which were available for all
patients. The last follow-up day was defined as the day
on which the last chest radiograph was conducted in
the study hospitals.
Definition and classification of treatment outcomes
Actinomycosis was confirmed by biopsy findings of
Gram-positive branching filamentous organisms on Gram
(or Gomori methenamine silver) staining or sulfur gran-
ules seen upon hematoxylin-eosin staining. Treatment
outcomes were defined as cure (complete resolution of the
main lesion after antibiotic treatment) or failure (persist-
ence or progression of the lesion or uncontrolled symp-
toms despite proper antibiotics therapy). If patients were
diagnosed with pathological or radiological evidence of re-
lapsed pulmonary actinomycosis after being cured, they
were classified as recurrent cases. Based on this classifica-
tion, the treatment outcome was further categorized into
good (cured) or poor (failure or recurrence) to identify
predictors of treatment outcome.






Mean age, years 58.4 ± 11.6 68
Sex, male (%) 47 (69.1) 68
Smoking 64
Never smoker 22 (34.4)
Current or ex-smoker 42 (65.6)
Alcohol drinking 61
Never drinker 32 (52.4)
Social drinker 20 (32.8)
Heavy drinker (>4 times/week) 9 (14.8)
Systemic disease 68
Diabetes mellitus 11 (16.2)
Malignancy 8 (11.8)
Chronic liver disease 4 (5.9)
Cerebral vascular accident 2 (2.9)
Chronic kidney disease 1 (1.5)





Lung cancer 2 (2.9)
Asthma 1 (1.5)
Educational background 51
Low (elementary, middle school) 14 (27.4)
Moderate (high school) 16 (31.4)
High (college) 21 (41.2)
Symptoms and signs 68
Cough 62 (91.2)
Sputum production 54 (79.4)
Hemoptysis 40 (58.8)
Massive hemoptysis 9 (13.2)




Chest CT findings 68
Consolidation 63 (92.6)
Central necrosis 42 (61.8)
Cavitation 13 (19.1)
Peripheral subpleural lesion 44 (64.7)
Pleural thickening 47 (69.1)
Focal pleural effusion 19 (27.9)
Mediastinal lymph node enlargement 27 (39.7)
Size of parenchymal lesion, mean
(cm, range)
3.9 (1.5-9.0)
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Statistical analysis
The duration of antibiotic treatment is expressed as the
median and range. Categorical variables were analyzed
using Pearson’s chi-square test or Fisher’s exact test. Con-
tinuous variables were analyzed using Student’s t-test or
Mann–Whitney U-test. All variables were assessed in the
univariate analyses. Age, sex, and variables showing a sig-
nificant correlation (p ≤ 0.1) were included in the multi-
variate logistic regression analysis. A p value < 0.05 was
considered to indicate statistical significance. All analyses
were performed using SPSS for Windows ver. 18.0 (SPSS,
Chicago, IL, USA).
Results
Baseline characteristics of the subjects
The baseline characteristics of the 68 patients are summa-
rized in Table 1. The mean ± SD age was 58.4 ± 11.6 years,
and 47 (69.1%) were male. Forty-two (65.6%) patients were
current or ex-smokers. Nine patients were heavy drinkers
who consumed alcohol more than four times per week.
None of the 68 patients tested positive for human im-
munodeficiency virus. No patient had used long-term sys-
temic corticosteroids. The most common symptoms were
cough (n = 62), followed by sputum production (n = 54)
and hemoptysis (n = 40). Massive hemoptysis defined as
> 200 mL/day occurred in 9 (13.2%) patients. Diagnostic
procedures were a non-surgical biopsy in 49 (72.1%) pa-
tients, CT-guided transthoracic needle aspiration or bi-
opsy in 39 (57.4%), bronchoscopic biopsy in nine (13.2%),
and endobronchial ultrasonography biopsy in one patient.
Clinical course
The mean follow-up duration was 37.7 (range 3.0–113.8)
months. Initially, 53/68 (77.9%) patients were treated only
with antibiotics and the other 15/68 (22.1%) patients
underwent surgical treatment followed by antibiotics
(Figure 1). Of the 53 patients who initially received anti-
biotic therapy, 45 (84.9%) were cured without relapse
(median antibiotic duration 5.3 months). Five of the 53
(9.4%) patients were medically refractory (median anti-
biotic duration 9.7 months) and three of 53 (5.7%)
patients experienced a recurrence (median time to re-
lapse 35.3 months, range 20.1–42.6). All of the five
medically refractory patients underwent rescue surgical
treatment and received antibiotics after surgery. Their
treatment was successful without complications. Of the
patients with recurrence, two underwent surgical treat-
ment and the other was treated using the same antibi-
otics as had been used successfully for the previous
episode. With initial surgical treatment, cure occurred in
14/15 (93.3%) and treatment failure in 1/15 (6.7%). This
surgical failure had used long-term antibiotics but did
not respond well, and a second operation was planned.
Fourteen of the 15 patients received oral antibiotic ther-
apy after surgery (median 5.1 (range 0.4–15.7) months).
One patient did not receive antibiotics after surgery (not
relapsed). There were no differences in treatment out-
comes regarding with or without initial surgical treatment
(Table 2).
Intravenous antibiotics
Thirty-eight (55.9%) patients initially received IV anti-
biotic treatment. The median duration was 7 (range 2–
21) days. Various IV antibiotics were used, including
third-generation cephalosporins (ceftriaxone, cefotaxime,
cefpiramide) (n = 12), aminopenicillin with or without
a β-lactamase inhibitor (ampicillin, amoxicillin) (n = 10),
oxacephem (flomoxef) (n = 5), first-generation cephalo-
sporins (cefazolin) (n = 4), penicillin (penicillin G) (n = 3),
quinolone (levofloxacin, moxifloxacin) (n = 3), and clinda-
mycin (n = 1). Among the five patients who failed initial
antibiotics, four (80%) did receive IV antibiotics. Neverthe-
less, the proportion of patients who did not use IV antibi-
otics was not significantly different between cured and
treatment-failed patients in the antibiotics-alone group
(54% vs. 80%, p = 0.374).
A comparison of treatment outcome with various oral
antibiotics
The oral antibiotic regimens and outcomes of patients
with pulmonary actinomycosis are shown in Table 3.
Patients received oral antibiotics either initially or after
Figure 1 Schematic of the clinical course in the patients with pulmonary actinomycosis.
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IV antibiotics. Most patients received an oral beta-
lactam with a beta-lactamase inhibitor (n = 55): amoxicil-
lin clavulanate (AMX-CLV) in 30 patients and ampicillin
sulbactam (AMP-SUL) in 25. Treatment failure occurred
in 3/30 (10%) patients receiving AMX-CLV and 2/25
(8%) receiving AMP-SUL, with 3/25 (12%) relapses in
the latter group. The AMX-CLV group had a higher cure
rate than the AMP-SUL group, but the difference was
not significant (90% vs. 80%, p = 0.295).
Comparison of patients with good and poor outcomes
A good outcome was achieved in 59/68 (86.8%) of the
cases and a poor outcome in 9/68 (13.2%), consisting of
treatment failed (8.8%) and relapse (4.4%) (Table 4). The
mean age of the poor outcome group was younger than
that of the good outcome group (51.0 vs. 59.6 years;
p = 0.038). The 1-month antibiotic response rate was sig-
nificantly higher in the good outcome group than in the
poor outcome group (92.7% vs. 22.2%; p < 0.001). There
was no significant difference regarding symptoms, size
of the parenchymal lesion, pulmonary comorbidities,
systemic disease, with or without of IV antibiotics, or
initial surgery. In the multivariate analysis, absence of a
1-month antibiotic response was an independent factor
associated with a poor outcome, with an adjusted odds
ratio of 49.2 (95% confidence interval (CI) 3.34–724.30).
Age, sex, and the presence of hemoptysis were not inde-
pendently associated with a poor outcome in the multi-
variate analysis (Table 5).
Discussion
Our data suggest that treatment failure or recurrence
of pulmonary actinomycosis is not uncommon. The
1-month antibiotic response was an independent pre-
dictor of the treatment outcome. This is the largest
published series of biopsy-proven cases of pulmonary
actinomycosis and is to our knowledge the first study
to evaluate the treatment outcome using a multivari-
ate analysis. The mean follow-up period of 37.7
months was also longer than in previous pulmonary
actinomycosis studies.
In our series, the classic presentation of pulmonary
actinomycosis with chest wall invasion and cutaneous
fistulas discharging sulfur granules was absent. This
was common in the pre-antibiotics era, but is now
rare [3]. The change might be the result of improve-
ments in oral hygiene, the ready availability of im-
aging modalities such as CT, and the early initiation
of antibiotics when pulmonary infection is suspected
[3]. A male predominance was noted and there were
a large number of smokers and drinkers. These are
consistent with the findings of earlier studies [6,11].
Table 2 Outcomes of pulmonary actinomycosis after treatment with antibiotics alone or with initial surgery followed
by antibiotics
Initial antibiotics treatment Initial surgical treatment Total
P value
(n = 53) (n = 15) (n = 68)
Treatment outcome P = 1.000
Cured 45 (84.9) 14 (93.3) 59 (86.8)
Failure 5 (9.4) 1 (6.7) 6 (8.8)
Relapse 3 (5.7) 0 (0.0) 3 (4.4)
Number of patients treated with IV antibiotics 23 (43.4) 15 (100.0) 38 (55.9) P < 0.001
Duration of antibiotics
IV antibiotics, day 6 (2–19) 8 (3–21) 7 (2–21) P = 0.022
Oral antibiotics, month 5.4 (1.2-14.0) 5.1 (0.4-15.7) 5.3 (0.4-15.7) P = 0.363
Table 3 Outcomes of treatment of pulmonary actinomycosis with various oral antibiotics
All patients (n = 68) Initial antibiotics alone (n = 53)
Cured Failure Relapse Total Cured Failure Relapse Total
AMX-CLV 27 (90.0) 3 (10.0) 0 (0) 30 25 (89.3) 3 (10.7) 0 (0.0) 28
AMP-SUL 20 (80.0) 2 (8.0) 3 (12.0) 25 10 (71.5) 1 (7.1) 3 (21.4) 14
Amoxicillin 4 (80.0) 1 (20.0) 0 (0) 5 3 (75.0) 1 (25.0) 0 (0) 4
Ampicillin 2 (100) 0 (0) 0 (0) 2 2 (100) 0 (0) 0 (0) 2
Clindamycin 3 (100) 0 (0) 0 (0) 3 2 (100) 0 (0) 0 (0) 2
Others 3 (100) 0 (0) 0 (0) 3 3 (100) 0 (0) 0 (0) 3
AMX-CLV; Amoxicillin clavulanate.
AMP-SUL; Ampicillin sulbactam.
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COPD and previous mycobacterial infection were the
most common underlying respiratory disorders, and
some patients had diabetes mellitus, as in previous studies
[6,12]. However, it is not clear whether an immunocom-
promised status is a risk factor for actinomycosis. For ex-
ample, the prevalence of actinomycosis was not increased
in patients with acquired immunodeficiency syndrome [3].
In fact, the majority of patients in our study were im-
munocompetent. Education status also did not influence
the incidence. A previous study also documented that
socioeconomic class per se did not appear to correlate
with the incidence of actinomycosis in the developed
world [5].
The definitive diagnosis of actinomycosis needs the
direct isolation of Actinomyces from a clinical specimen.
However, cultures are positive in only a few cases be-
cause of failure of the anaerobic organism to grow [1].
The diagnosis is often based on histopathology showing
Gram-positive filamentous branching bacteria and sulfur
granules. All of our patients were diagnosed from biop-
sies. Microbiological cultures were performed for the bi-
opsy specimens in 26 patients. However, the results were
positive in only one patient.
Our treatment outcome for pulmonary actinomycosis
consisted of a cure rate of 86.8% (59/68), failure rate of
8.8% (6/68), and relapse rate of 4.4% (3/68). There was no
mortality from pulmonary actinomycosis. One patient
died of metastatic gastric cancer 3 years after finishing
successful treatment. Previously, our group reported 25
cases of pulmonary actinomycosis, and one patient died of
a bronchopleural fistula (BPF) and empyema after a pneu-
monetomy [13]. Song et al. [6] reported an overall cure
rate of 85% (34/40) in pulmonary actinomycosis without
mentioning recurrence. They also experienced one case of
postoperative mortality due to a BPF. Choi et al. [10] re-
ported a 100% cure rate in 26 cases without recurrence,
despite a relatively short follow-up duration (median 23
months). Possible explanations for treatment failure are
drug-resistant co-pathogens and poor penetration of the
drug caused by avascularity and induration of the infected
area [14]. Although reported antimicrobial susceptibility
tests indicate that most Actinomyces are susceptible to
penicillin and amoxicillin, Actinomyces may acquire anti-
biotic resistance during antibiotic treatment [15,16].
There are no guidelines regarding the appropriate dur-
ation of antibiotic treatment. Recently, several investiga-
tors reported that shorter courses of treatment could be
successful in pulmonary actinomycosis [10]. However,
Kolditz et al. [12] reported that antibiotic treatment for
less than 3 months in medically treated patients might
be associated with local complications or recurrence.
We managed cases of pulmonary actinomycosis with
antibiotic treatment for less than 6 months. Further-
more, prolonged treatment did not prevent recurrence
Table 4 Comparison of pulmonary actinomycosis patients






(n = 59) (n = 9)
Gender, male (%) 41 (69.5) 6 (66.7) 0.864
Mean age, years 59.6 ± 11.3 51.0 ± 11.3 0.038
Size of parenchymal lesion 3.7 (1.5-9.0) 5.2 (2.6-7.0) 0.093
Current smoker 17/56 (30.4) 3/8 (37.5) 0.697
Heavy alcoholics 7/52 (13.5) 2/9 (22.2) 0.609
Pulmonary comorbidity 21 (35.6) 4 (44.4) 0.608




25 (42.4) 5 (56.6) 0.458
White blood cell, ×103/μL 7.9 (2.6–33.1) 8.0 (3.8–13.2) 0.246
CRP, mg/dL 1.5 (0.1–38.0) 4.3 (0.1–6.72) 0.726
Serum albumin, g/dL 3.9 (1.2–4.7) 3.8 (2.9–4.6) 0.450
Systemic disease
Diabetes mellitus 11 1 1.000
Malignancy 6 (75.0) 2 (25.0) 0.335
1 month after initial
antibiotic therapy
Responder 38/41 (92.7) 2/9 (22.2) < 0.001
Non responder 3/41 (7.3) 7/9 (77.8)
Patients who did not use
IV antibiotics
25 (42.4) 5 (55.6) 0.493
Antibiotics duration
IV antibiotics, day 7 (2–21) 7 (5–8) 0.951
Initial therapy, months 5.3 (0.4-13.0) 10.2 (2.1–15.7) 0.061
With rescue therapy,
months
5.3 (0.4–13.0) 13.2 (5.9–33.1) < 0.001
Table 5 Clinical factors associated with a poor treatment outcome in patients with pulmonary actinomycosis
Univariate analysis Multivariate analysis
P value Crude OR (95% CI) P value Adjusted OR (95% CI)
Age (continuous variable) 0.047 0.93 (0.86–0.99) 0.630 1.03 (0.93–1.13)
Male gender 0.864 0.89 (0.20–3.91) 0.609 1.84 (0.18–18.44)
Hemoptysis 0.080 6.75 (0.79–57.43) 0.305 3.97 (0.29–55.31)
Non response after 1 month < 0.001 44.33 (6.23–315.50) 0.003 49.20 (3.34–724.30)
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in three patients (range 9.2–14.0 months). It is not clear
why these cases recurred: one was a current smoker and
heavy drinker, but the other two had never smoked and
did not consume alcohol. Considering the time to re-
currence in our study, a reasonable follow-up duration
should be at least 3 years.
Whether IV antibiotics should be used in the early man-
agement of actinomycosis remains uncertain. More than
half of our medically treated patients were treated success-
fully without IV antibiotics. Furthermore, the median dur-
ation of IV antibiotics was less than 1 week in the group
given IV antibiotics. Choi et al. [10] also reported that 7 of
15 medically treated patients with thoracic actinomycosis
were treated successfully with oral antibiotics only. There-
fore, the previous recommendation of IV antibiotics for 2–
6 weeks might not be appropriate for all patients.
Penicillin G has been recommended as the drug of choice
for treatment [2]. However, no comparative study has in-
vestigated which antibiotics are superior. To our know-
ledge, only two in vitro studies have reported Actinomyces
drug susceptibility [15,16]. Recent reviews recommend that
the first-line regimen consist of a beta-lactam and beta-
lactamase inhibitor [1,16,17]. A beta-lactamase inhibitor of-
fers the advantage of coverage against penicillin-resistant
aerobic and anaerobic co-pathogens. These microorgan-
isms produce the enzyme beta-lactamase, which can shield
Actinomyces from the effect of penicillin. Furthermore, they
might assist the spread of infection by inhibiting host
defenses and reducing local oxygen tension [17]. In com-
parisons of AMX-CLV with AMP-SUL, the outcome of
treatment with the latter tends to be poor. A possible ex-
planation for this result is that sulbactam is a less potent
beta-lactamase inhibitor than clavulanate in vitro [18], and
ampicillin peak levels are delayed and lowered if it is
ingested with food [19]. A prospective clinical trial would
be the proper approach.
There are no definitive guidelines for when surgical
intervention is required. Surgery is needed if a malig-
nancy cannot be excluded [1]. It might also be used
to control severe symptoms, such as uncontrolled
hemoptysis [3]. Surgery could be a rescue treatment
for patients who do not respond to antibiotics [6]. In
our study, one of nine patients who presented with
massive hemoptysis underwent emergency surgery.
Bronchial artery embolization was attempted in the
other eight patients, of whom seven ultimately needed
surgery for continuing bleeding or for definitive diag-
nosis. Other indications for surgery include drainage
of an abscess or pleural empyema, decortication, and
the radical excision of sinus tracts [14].
One of our most important findings was that the 1-
month antibiotic response and treatment outcome were
closely associated according to the multivariate anal-
ysis. According to previous case reports, pulmonary
actinomycosis usually decreases in size on the chest radio-
graph within 4 weeks [20]. A recent study also reported
that only 20% (1/5) of patients with treatment failure
showed any response to antibiotics within 4 weeks [6].
In addition, long-term antibiotics could not guarantee a
successful outcome or no relapse in our series. The ab-
sence of an early radiological response might be an im-
portant predictor of a poor outcome. We did not find a
significant difference in treatment outcomes based on
treatment modality.
This study had several limitations. First, given it's retro-
spective nature, selection bias may have influenced the sig-
nificance of our results. The sample size of the study was
too small to obtain a strong conclusion. Additionally,
many treatment options were used, and this might have
influenced the statistical power. Second, there were no
predetermined criteria for halting treatment. Antibiotics
were stopped in most patients based on radiological and
clinical resolution of their pulmonary actinomycosis.
Third, we did not evaluate the correlation between drug
susceptibility test results and treatment outcome.
Conclusion
In conclusion, antibiotic treatment with or without surgery
was effective for treatment of pulmonary actinomycosis.
The duration of treatment for pulmonary actinomycosis
can be shorter than traditionally recommended. Neverthe-
less, treatment failure and recurrence are not uncommon.
Therefore, close monitoring and follow-up are necessary
for a successful outcome. In addition, the early antibiotic
response can predict treatment outcome, and might have a
role in patient follow-up.
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